Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir
Open Access
- 1 January 2005
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (1) , 467-469
- https://doi.org/10.1128/aac.49.1.467-469.2005
Abstract
Single doses of MAALOX TC and ranitidine were administered separately with 1,400 mg of fosamprenavir (FPV). MAALOX TC decreased the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) for plasma amprenavir (APV) by 18% and the maximum concentration of drug in serum ( C max ) by 35%; the plasma APV concentration at 12 h ( C 12 ) increased by 14%. Ranitidine at 300 mg decreased the AUC 0-24 for plasma APV by 30% and C max by 51%; C 12 was unchanged. FPV may be coadministered with antacids without concern and without separation in dosing; however, caution is recommended when FPV is coadministered with histamine 2 - receptor antagonists or proton pump inhibitors.Keywords
This publication has 10 references indexed in Scilit:
- Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor AmprenavirAntimicrobial Agents and Chemotherapy, 2004
- Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral DosingAntimicrobial Agents and Chemotherapy, 2001
- Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudineAIDS, 2000
- Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination TherapyAntimicrobial Agents and Chemotherapy, 2000
- Indinavir Concentrations and Antiviral EffectPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
- Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavirAIDS, 1997
- Effervescent and standard formulations of ranitidine—a comparison of their pharmacokinetics and pharmacologyAlimentary Pharmacology & Therapeutics, 1996
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996